Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 118Neoplasms 14Neoplasm Metastasis 14Multiple Endocrine Neoplasia Type 1 5Advanced Breast Cancer 5Prostatic Neoplasms 3Hereditary Sensory and Autonomic Neuropathies 3Breast Cancer Metastatic 3Recurrence 2Lymphoma 2Lung Neoplasms 2Endometrial Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Solid Malignancies 1Small Cell Lung Carcinoma 1Sex Cord-Gonadal Stromal Tumors 1Sarcoma, Endometrial Stromal 1Postmenopausal Women With ER+ HER2- Primary Breast Cancer 1Patient Acceptance of Health Care 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplastic Cells, Circulating 1Neoplasms by Site 1Mesothelioma, Malignant 1Mesothelioma 1Lymphoma, Non-Hodgkin 1Lethal Congenital Contracture Syndrome 2 1Hyperglycemia 1

Interventions

Letrozole 2palbociclib 1Fulvestrant 1Diet, Ketogenic 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Estrogen Receptor-positive Breast Cancer × Fulvestrant × Clear all
NCT03633331 2026-04-29

Palbociclib and Letrozole or Fulvestrant in Treating Patients With Estrogen Receptor Positive, HER2 Negative Metastatic Breast Cancer

Alliance for Clinical Trials in Oncology

Phase 2 Completed
93 enrolled 16 charts
Breast

Estrogen Receptor-positive Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡